Logo image of PIII

P3 HEALTH PARTNERS INC (PIII) Stock Fundamental Analysis

NASDAQ:PIII - US7444132044 - Common Stock

8.7742 USD
+0.01 (+0.12%)
Last: 9/5/2025, 8:00:01 PM
Fundamental Rating

1

Overall PIII gets a fundamental rating of 1 out of 10. We evaluated PIII against 102 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of PIII have multiple concerns. PIII is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PIII had negative earnings in the past year.
In the past year PIII has reported a negative cash flow from operations.
In the past 5 years PIII always reported negative net income.
PIII had a negative operating cash flow in each of the past 5 years.
PIII Yearly Net Income VS EBIT VS OCF VS FCFPIII Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -19.95%, PIII is doing worse than 82.35% of the companies in the same industry.
The Return On Equity of PIII (-328.33%) is worse than 79.41% of its industry peers.
Industry RankSector Rank
ROA -19.95%
ROE -328.33%
ROIC N/A
ROA(3y)-18.29%
ROA(5y)-20.52%
ROE(3y)-1599.17%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PIII Yearly ROA, ROE, ROICPIII Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PIII so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PIII Yearly Profit, Operating, Gross MarginsPIII Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40 -50

More info and screens

0

2. Health

2.1 Basic Checks

PIII does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PIII has been increased compared to 1 year ago.
PIII has more shares outstanding than it did 5 years ago.
PIII has a worse debt/assets ratio than last year.
PIII Yearly Shares OutstandingPIII Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 1M 2M 3M
PIII Yearly Total Debt VS Total AssetsPIII Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of -0.96, we must say that PIII is in the distress zone and has some risk of bankruptcy.
PIII has a Altman-Z score of -0.96. This is amonst the worse of the industry: PIII underperforms 82.35% of its industry peers.
PIII has a Debt/Equity ratio of 2.30. This is a high value indicating a heavy dependency on external financing.
PIII's Debt to Equity ratio of 2.30 is on the low side compared to the rest of the industry. PIII is outperformed by 74.51% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.3
Debt/FCF N/A
Altman-Z -0.96
ROIC/WACCN/A
WACC10.85%
PIII Yearly LT Debt VS Equity VS FCFPIII Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

PIII has a Current Ratio of 0.31. This is a bad value and indicates that PIII is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of PIII (0.31) is worse than 92.16% of its industry peers.
PIII has a Quick Ratio of 0.31. This is a bad value and indicates that PIII is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of PIII (0.31) is worse than 91.18% of its industry peers.
Industry RankSector Rank
Current Ratio 0.31
Quick Ratio 0.31
PIII Yearly Current Assets VS Current LiabilitesPIII Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for PIII have decreased strongly by -57.66% in the last year.
PIII shows a small growth in Revenue. In the last year, the Revenue has grown by 4.20%.
Measured over the past years, PIII shows a very strong growth in Revenue. The Revenue has been growing by 59.38% on average per year.
EPS 1Y (TTM)-57.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.44%
Revenue 1Y (TTM)4.2%
Revenue growth 3Y33.03%
Revenue growth 5Y59.38%
Sales Q2Q%-6.16%

3.2 Future

The Earnings Per Share is expected to grow by 25.98% on average over the next years. This is a very strong growth
PIII is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.14% yearly.
EPS Next Y62.59%
EPS Next 2Y36.37%
EPS Next 3Y25.98%
EPS Next 5YN/A
Revenue Next Year-5.14%
Revenue Next 2Y1.9%
Revenue Next 3Y2.14%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
PIII Yearly Revenue VS EstimatesPIII Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
PIII Yearly EPS VS EstimatesPIII Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -50 -100 -150 -200 -250

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PIII. In the last year negative earnings were reported.
Also next year PIII is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PIII Price Earnings VS Forward Price EarningsPIII Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PIII Per share dataPIII EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 -50 100 150 200

4.3 Compensation for Growth

PIII's earnings are expected to grow with 25.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.37%
EPS Next 3Y25.98%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PIII!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

P3 HEALTH PARTNERS INC

NASDAQ:PIII (9/5/2025, 8:00:01 PM)

8.7742

+0.01 (+0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-10 2025-11-10
Inst Owners11.28%
Inst Owner Change-97.99%
Ins Owners2.7%
Ins Owner Change0.01%
Market Cap63.09M
Analysts78
Price Target13.94 (58.87%)
Short Float %2.02%
Short Ratio2.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.04%
Min EPS beat(2)-28.86%
Max EPS beat(2)30.94%
EPS beat(4)1
Avg EPS beat(4)-255.59%
Min EPS beat(4)-658.17%
Max EPS beat(4)30.94%
EPS beat(8)2
Avg EPS beat(8)-149.43%
EPS beat(12)5
Avg EPS beat(12)-99.66%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-2.63%
Max Revenue beat(2)2.11%
Revenue beat(4)1
Avg Revenue beat(4)-1.74%
Min Revenue beat(4)-3.87%
Max Revenue beat(4)2.11%
Revenue beat(8)3
Avg Revenue beat(8)0.83%
Revenue beat(12)6
Avg Revenue beat(12)0.99%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.65%
PT rev (3m)-47.44%
EPS NQ rev (1m)-51.42%
EPS NQ rev (3m)-37.27%
EPS NY rev (1m)-4.18%
EPS NY rev (3m)26.96%
Revenue NQ rev (1m)-0.18%
Revenue NQ rev (3m)1.12%
Revenue NY rev (1m)-0.34%
Revenue NY rev (3m)0.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.04
P/FCF N/A
P/OCF N/A
P/B 1.42
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-46.51
EYN/A
EPS(NY)-6.53
Fwd EYN/A
FCF(TTM)-18.07
FCFYN/A
OCF(TTM)-18.07
OCFYN/A
SpS203.31
BVpS6.18
TBVpS-68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.95%
ROE -328.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-18.29%
ROA(5y)-20.52%
ROE(3y)-1599.17%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover2
Health
Industry RankSector Rank
Debt/Equity 2.3
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.31
Quick Ratio 0.31
Altman-Z -0.96
F-Score4
WACC10.85%
ROIC/WACCN/A
Cap/Depr(3y)1.55%
Cap/Depr(5y)81.99%
Cap/Sales(3y)0.12%
Cap/Sales(5y)0.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-57.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-38.44%
EPS Next Y62.59%
EPS Next 2Y36.37%
EPS Next 3Y25.98%
EPS Next 5YN/A
Revenue 1Y (TTM)4.2%
Revenue growth 3Y33.03%
Revenue growth 5Y59.38%
Sales Q2Q%-6.16%
Revenue Next Year-5.14%
Revenue Next 2Y1.9%
Revenue Next 3Y2.14%
Revenue Next 5YN/A
EBIT growth 1Y-78.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year84.44%
EBIT Next 3Y27.86%
EBIT Next 5YN/A
FCF growth 1Y-20.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.19%
OCF growth 3YN/A
OCF growth 5YN/A